Radiation Therapy for Breast Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, you cannot participate if you are undergoing concurrent cytotoxic chemotherapy.
What data supports the effectiveness of the treatment Whole Breast Irradiation with Simultaneous Integrated Boost for breast cancer?
Research shows that using intensity-modulated radiation therapy (IMRT) with a simultaneous integrated boost (SIB) can improve dose distribution and reduce treatment time for breast cancer patients. Studies also suggest that this approach may reduce acute side effects compared to traditional methods.12345
Is radiation therapy with simultaneous integrated boost safe for breast cancer patients?
Research shows that intensity-modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) is generally safe for breast cancer patients, with reduced acute toxicities (short-term side effects) compared to traditional methods. Long-term studies also support its safety, especially in elderly patients.12346
How is the treatment Whole Breast Irradiation with Simultaneous Integrated Boost different from other breast cancer treatments?
This treatment is unique because it uses intensity-modulated radiation therapy (IMRT) to deliver a higher dose of radiation directly to the tumor area while simultaneously treating the whole breast, which can shorten the overall treatment time and reduce side effects compared to traditional methods.12347
What is the purpose of this trial?
This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will be on study for up to 60 months.
Research Team
Jessica Schuster, MD
Principal Investigator
UW Carbone Cancer Center
Eligibility Criteria
This trial is for women with breast cancer who are eligible for radiation therapy. Specific eligibility details aren't provided, but typically participants must be in good health aside from their cancer and meet certain medical criteria.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB) over 5 treatment visits
Follow-up
Participants are monitored for cosmetic outcomes, patient-reported outcomes, and toxicities at multiple intervals post-treatment
Treatment Details
Interventions
- Whole Breast Irradiation with Simultaneous Integrated Boost
Whole Breast Irradiation with Simultaneous Integrated Boost is already approved in United States, European Union, Canada for the following indications:
- Early-stage breast cancer
- Early-stage breast cancer
- Early-stage breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor